All Oncology News

Subgroup Analysis Shows Consistent Benefit for Dostarlimab Plus Chemo in Nonsquamous NSCLC

April 24th 2023

Overall response rates were similar across subgroups of patients with nonsquamous non–small cell lung cancer for the combinations of dostarlimab-gxly plus chemotherapy and pembrolizumab plus chemotherapy, and responses numerically favored the dostarlimab-based combination in most subgroups, according to a subgroup analysis of the phase 2 PERLA trial.

Study: Vitamin D May Play a Role in Prostate Cancer Disparities

April 24th 2023

Vitamin D deficiency could be the reason African American men experience more aggressive prostate cancer at a younger age compared with European American men.

Sugemalimab Monotherapy Has Clinical Benefit in NK/T-Cell Lymphoma

April 24th 2023

The PD-L1 inhibitor sugemalimab produced durable responses with a tolerable safety profile in patients with relapsed/refractory natural killer/T-cell lymphoma, according to findings from a preplanned primary analysis of the multicenter, single-arm, phase 2 GEMSTONE-201 trial.

Ribociclib Plus Letrozole Has Activity in Recurrent Low-Grade Serous Ovarian Cancer

April 24th 2023

Brian M. Slomovitz, MD, discusses key efficacy and safety data seen with ribociclib and letrozole in the GOG 3026 trial and planned efforts to identify associated biomarkers and pursue FDA approval for the combination in advanced, recurrent low-grade serous ovarian cancer.

PARP Inhibitors, ADCs, and Immunotherapy Approaches Advance the Treatment Paradigm in Gynecologic Oncology

April 24th 2023

Joshua G. Cohen, MD, FACOG, FACS, expands on the role of PARP inhibitors in the recurrent and up-front settings in ovarian cancer, and the clinical significance of the RUBY and NY-GY018 trials in endometrial cancer.

LY3537982 Demonstrates Tolerability and Preliminary Efficacy in KRAS G12C–mutated Advanced Solid Tumors

April 23rd 2023

Joshua K. Sabari, MD, shares how the unique pharmacokinetics and mechanism of action for LY3537982 supported its investigation in the LOXO-RAS- 20001 study, findings presented at AACR, and how this research could address unmet needs in patients with KRAS G12C–mutant solid tumors.

Long-term Outcomes From JAVELIN Bladder 100 Solidify Maintenance Avelumab as SOC in Metastatic Urothelial Carcinoma

April 22nd 2023

A long-term post-hoc analysis from the JAVELIN Bladder 100 trial demonstrated that first-line maintenance avelumab elicited similar overall survival and progression-free survival benefits vs best supportive care alone in patients with advanced urothelial carcinoma.

Tucatinib/Trastuzumab Approval Highlights Expansion of Tailored Therapies in HER2+ CRC

April 21st 2023

John L. Hays, MD, PhD, discusses the importance of tailoring therapies for patients with CRC who express HER2 or have other actionable targets, the need to develop optimal sequences for local and systemic therapy in CRC, and key updates in hepatocellular carcinoma and pancreatic cancer.

Selinexor/Ruxolitinib Combo Elicits Sustained Spleen Responses, Improves Symptoms in Myelofibrosis

April 21st 2023

The combination of selinexor at 60 mg and ruxolitinib induced rapid and durable spleen responses and improved symptoms at weeks 12 and 24 in patients with treatment-naïve myelofibrosis, according to updated data from the phase 1 XPORT-MF-034 trial.

Batiraxcept Plus Cabozantinib Has Tolerable Safety Profile in Metastatic Clear Cell RCC

April 21st 2023

The combination of batiraxcept and cabozantinib is safe and generated early evidence of efficacy in pretreated patients with advanced or metastatic clear cell renal cell carcinoma.

Fox Chase Cancer Center Clinical Director Wins Oncology Nursing Society’s Excellence in Cancer Nursing Management Award

April 21st 2023

Erin Longstreth-Papsun, RN, MSN, OCN, NEA-BC, clinical director of Ambulatory Satellite Clinics and Radiation Oncology Nursing at Fox Chase Cancer Center, was recently awarded the Excellence in Cancer Nursing Management Award by the Oncology Nursing Society (ONS).

Tislelizumab Plus Chemotherapy Meets OS End Point in Advanced Gastric/GEJ Adenocarcinoma

April 21st 2023

The combination of tislelizumab plus chemotherapy elicited a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy plus placebo in patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

O’Shaughnessy Showcases Highlights in Breast Cancer Guiding 2023 IBC Congresses

April 21st 2023

Joyce A. O’Shaughnessy, MD, highlights multidisciplinary approaches including discussions on tumor boards, and discusses how to better assist patients with accessing care, and notable advances in the field particularly with the HER2 classification.

FDA Extends Review for Quizartinib in Newly Diagnosed FLT3-ITD+ AML

April 21st 2023

The FDA has extended the review period for a new drug application for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of newly diagnosed adult patients with FLT3-ITD–positive acute myeloid leukemia.

Novel Methylation-Based Platform Shows Promise for Multicancer Early Detection

April 21st 2023

A genome-wide methylome enrichment platform demonstrated efficacy in detecting early-stage, low-shedding cancers with limited circulating tumor DNA.

Endoscopic Strategies Broaden the Pancreatic Cancer Diagnostic and Treatment Paradigms

April 20th 2023

In pancreatic cancer, the role of the endoscopist continues to evolve as technologies like endoscopic ultrasound–guided biopsies present clinicians with increasingly accurate information to characterize the tumor microenvironments of individual patients and determine effective targeted therapies.

BASECAMP-1 Aims to Identify Patients Eligible for Treatment With Novel CAR T-Cell Agent

April 20th 2023

Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial, with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530.

Expanded Genomic and Early-Detection Testing Define Next Level of Precision Oncology Screening and Management

April 20th 2023

Head and Neck, Breast cancer Research Highlights AACR Abstracts

April 20th 2023

University of Cincinnati Cancer Center researchers presented more than a dozen abstracts at the 2023 American Association for Cancer Research Annual Meeting, including findings that could advance treatments for head and neck and breast cancers.

VB10.16 Plus Atezolizumab Generates Positive Survival Data in PD-L1+ Advanced Cervical Cancer

April 20th 2023

The combination of the potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate VB10.16 and atezolizumab elicited a median overall survival greater than 25 months in patients with PD-L1–positive, human papillomavirus 16–positive advanced cervical cancer.